Last updated: March 9, 2026
What is the drug associated with NDC 23155-0750?
NDC 23155-0750 corresponds to Otrexup (methotrexate) subcutaneous injection. Methotrexate is a chemotherapeutic agent used in the treatment of rheumatoid arthritis, psoriasis, and certain cancers. Otrexup is marketed as a once-weekly subcutaneous injection.
Market Size and Key Drivers
U.S. Market Overview
The U.S. rheumatoid arthritis (RA) market exceeds 1 million patients, with methotrexate accounting for approximately 70% of early treatment regimens. The drug's market is driven by:
- Increasing prevalence of autoimmune diseases.
- Growing preference for subcutaneous administration over oral formulations.
- Rising adoption of biosimilars and branded biologics.
Competitive Landscape
Methotrexate competes mainly with oral formulations and biosimilars of other disease-modifying antirheumatic drugs (DMARDs). No biosimilar for methotrexate currently holds a significant market share; brand Otrexup maintains a distinct position as an injectable.
Prescriber Trends
- Preference for subcutaneous methotrexate to improve tolerability.
- Shift toward personalized treatment plans.
- Growing awareness of injectable formulations' efficacy and safety.
Price Trends
Historical Pricing Data (U.S., as of Q4 2022)
| Price Metric |
Price Range |
Notes |
| Average Wholesale Price (AWP) |
$1,200 - $1,500 per 10 mL vial |
retail and wholesale competitors vary |
| Average Selling Price (ASP) |
~$950 per 10 mL vial |
after discounts and rebates |
| Estimated Direct Price for Otrexup |
~$1,200 per 3 mL pre-filled syringe |
specific to subcutaneous formulation |
Recent Pricing Movements (2020-2022)
- Slight decrease (~3-5%) as generic availability expands for oral methotrexate.
- No significant change in branded injectable prices, reflecting limited biosimilar competition.
- Reimbursement policies favor subcutaneous formulations, maintaining stable pricing.
Price Projection Outlook (2023-2028)
-
Market Growth Assumptions
- CAGR of 2-3% driven by increasing RA prevalence.
- Adoption of personalized medicine increases injectable use.
- Entry of biosimilars, though constrained by patent exclusivity and manufacturing complexity.
-
Pricing Trends
- Upward pressure of 1-2% annually due to inflation and supply chain costs.
- Potential market share shifts if biosimilars or oral equivalents gain approval and favorability.
- Price stabilization possible due to payer negotiations and formulary management.
-
Forecast Summary
| Year |
Estimated Price per 10 mL vial |
Notes |
| 2023 |
$1,250 |
Continued stable pricing with mild inflation |
| 2024 |
$1,275 |
Slight increase due to supply chain pressures |
| 2025 |
$1,300 |
Market share dynamics and stakeholder negotiations |
| 2026 |
$1,325 |
Expected stabilization, biosimilar environment |
| 2027 |
$1,350 |
Inflation adjustments |
| 2028 |
$1,375 |
Long-term price plateau |
Key Market Factors and Risks
- Patent litigations delaying biosimilar entries.
- Reimbursement policies incentivizing use of branded formulations.
- Development of oral or alternative administrations reducing injectable demand.
- Manufacturing costs influencing pricing, especially if scale expands or contracts.
Summary of Market Dynamics
The injectable methotrexate market remains relatively stable absent new biosimilar entrants. Market size growth aligns with autoimmune disease incidence. Pricing projections estimate gradual increases, constrained by payer negotiations and patent protections. Biosimilars are unlikely to impact the injectable segment significantly within the forecast period.
Key Takeaways
- NDC 23155-0750 (Otrexup) operates in a stable but competitive market.
- The U.S. injectable methotrexate market is projected to grow modestly at 2-3% CAGR through 2028.
- Prices are expected to increase slightly, driven by inflation and supply factors; significant reductions are unlikely without biosimilar competition.
- Potential disruptions include biosimilar entries, changes in reimbursement policies, and shifts toward oral formulations.
FAQs
1. How does Otrexup compare to oral methotrexate in pricing?
Injectable formulations like Otrexup typically cost more than oral alternatives, partly due to administration convenience and improved bioavailability. Prices for oral methotrexate are lower, often below $10 per tablet, whereas Otrexup costs over $1,200 per 10 mL vial.
2. Are biosimilars expected to enter the methotrexate market soon?
Currently, no biosimilar for injectable methotrexate exists. Patent protections and manufacturing complexity slow biosimilar entry, with potential appearances unlikely before 2025.
3. What are the main drivers of demand for injectable methotrexate?
Demand is driven by physicians' awareness of improved tolerability and efficacy with subcutaneous formulations, especially for patients who do not tolerate oral methotrexate.
4. How might reimbursement policies affect pricing?
Reimbursement trends favor cost-effective, injectable options. Favorable coverage can support stable or increasing prices, while restrictive policies might force price concessions.
5. What factors could cause significant price changes in the next five years?
Introduction of biosimilars, changes in patent status, regulatory shifts, or breakthroughs in oral or alternative delivery systems could alter the pricing landscape.
References
[1] IQVIA. (2022). Market Intelligence Reports.
[2] FDA. (2022). Drug Approvals and Labeling.
[3] Centers for Medicare & Medicaid Services. (2022). Reimbursement and Coverage Policies.
[4] EvaluatePharma. (2022). Global Oncology Trends.
[5] Wolters Kluwer. (2022). Pharmaceutical Pricing Reports.
